Challenges and Feasible Solutions of CART Therapy in Solid Tumors
DOI:
https://doi.org/10.61173/db2q9t74Keywords:
solid tumors, antigen recognition, tumor specificity, CAR-T cellsAbstract
CAR-T cell therapy has emerged as a significant advancement in cancer immunotherapy, particularly in treating hematologic malignancies with notable success. Yet, its efficacy in addressing complex solid tumors remains constrained. A principal challenge in the deployment of chimeric antigen receptor T-cell therapy for solid tumors lies in the limited availability of tumor-specific target antigens. Presently, the field of CAR-T cell research is marked by the limited availability of antigens that are genuinely specific to tumors. Even if tumor-specific antigens with high specificity can be identified, the heterogeneity of their expression in tumor tissues often further complicates the treatment. This review aims to delve into the issue of tumor-specific antigens and, based on current research progress, propose strategies for improving the search for new tumor antigens and CAR structural design to provide reasonable theoretical support and practical guidance for the safe and effective targeting of solid tumors by CART cells. By continuously optimizing the treatment strategies of CAR-T cell therapy, we aim to offer solid tumor patients more precise and efficient immunotherapy.
References
[1] Schuster, S.J. et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. NEW ENGL J MED 377, 2545-2554 (2017).
[2] Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. NAT MED 24, 541-550 (2018).
[3] Grigor, E.J.M. et al. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. TRANSFUS MED REV 33, 98-110 (2019).
[4] Kenderian, S.S. et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. LEUKEMIA 29, 1637- 1647 (2015).
[5] Gill, S.I. How close are we to CAR T-cell therapy for AML? BEST PRACT RES CL HA 32, 101104 (2019).
[6] Morgan, R.A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. MOL THER 18, 843-851 (2010).
[7] McGowan, E. et al. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. BIOMED PHARMACOTHER 121, 109625 (2020).
[8] Jiang, Z. et al. HIV-1-Specific CAR-T Cells With Cell-Intrinsic PD-1 Checkpoint Blockade Enhance Anti-HIV Efficacy in vivo. FRONT MICROBIOL 12 (2021).
[9] Nap, M., Mollgard, K., Burtin, P. & Fleuren, G.J. Immunohistochemistry of Carcino-Embryonic Antigen in the Embryo, Fetus and Adult. Tumor biology 9, 145-153
[10] Zhang, C. et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. MOL THER 25, 1248-1258 (2017).
[11] Chang, K. & Pastan, I. Molecular Cloning of Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas, and Ovarian Cancers. Proceedings of the National Academy of Sciences - PNAS 93, 136-140 (1996).
[12] Thomas, A.M. et al. Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients. The Journal of Experimental Medicine 200, 297- 306 (2004).
[13] Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences - PNAS 106, 3360-3365
[14] Adusumilli, P.S. et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab. CANCER DISCOV 11, 2748-2763 (2021).
[15] Sahin, U. et al. Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. CLIN CANCER RES 14, 7624-7634 (2008).
[16] Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. NAT MED 28, 1189-1198 (2022).
[17] Mazor, Y. et al. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. SCI REP-UK 7 (2017).
[18] Langan, R.A. et al. De novo design of bioactive protein switches. NATURE 572, 205-210 (2019).
[19] Lajoie, M.J. et al. Designed protein logic to target cells with precise combinations of surface antigens. SCIENCE 369, 1637-1643 (2020).
[20] Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J CLIN IN- VEST 126, 3036-3052 (2016).
[21] Schneider, D. et al. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J IMMUNOTHER CANCER 5 (2017).
[22] Morsut, L. et al. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. CELL 164, 780-791 (2016).
[23] Roybal, K.T. et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. CELL 164, 770-779 (2016).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
